Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The event is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to addressing unmet needs in mental health through its proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s pipeline includes HLP003, a Phase 3 NSA for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, a Phase 2 NSA for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company’s website at www.helus.com or follow on X, LinkedIn, YouTube, and Instagram.
The full press release is available at https://ibn.fm/1QdP7.
